Industry
Biotechnology
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Loading...
Open
5.25
Mkt cap
69M
Volume
409K
High
5.36
P/E Ratio
-1.18
52-wk high
22.49
Low
5.00
Div yield
N/A
52-wk low
4.53
Portfolio Pulse from
December 04, 2024 | 7:30 pm
Portfolio Pulse from
November 25, 2024 | 1:15 pm
Portfolio Pulse from Benzinga Newsdesk
October 16, 2024 | 4:01 pm
Portfolio Pulse from Benzinga Newsdesk
October 16, 2024 | 11:08 am
Portfolio Pulse from Benzinga Newsdesk
October 15, 2024 | 4:38 pm
Portfolio Pulse from Benzinga Newsdesk
October 15, 2024 | 1:24 pm
Portfolio Pulse from Benzinga Newsdesk
October 15, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Newsdesk
October 01, 2024 | 11:08 am
Portfolio Pulse from Benzinga Newsdesk
September 30, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 8:21 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.